PMID- 29494679 OWN - NLM STAT- MEDLINE DCOM- 20180626 LR - 20210109 IS - 1553-7374 (Electronic) IS - 1553-7366 (Print) IS - 1553-7366 (Linking) VI - 14 IP - 3 DP - 2018 Mar TI - Wolbachia-mediated virus blocking in mosquito cells is dependent on XRN1-mediated viral RNA degradation and influenced by viral replication rate. PG - e1006879 LID - 10.1371/journal.ppat.1006879 [doi] LID - e1006879 AB - Wolbachia is currently being developed as a novel tool to block the transmission of dengue viruses (DENV) by Aedes aegypti. A number of mechanisms have been proposed to explain the DENV-blocking phenotype in mosquitoes, including competition for fatty acids like cholesterol, manipulation of host miRNAs and upregulation of innate immune pathways in the mosquito. We examined the various stages in the DENV infection process to better understand the mechanism of Wolbachia-mediated virus blocking (WMVB). Our results suggest that infection with Wolbachia does not inhibit DENV binding or cell entry, but reduces virus replication. In contrast to a previous report, we also observed a similar reduction in replication of West Nile virus (WNV). This reduced replication is associated with rapid viral RNA degradation in the cytoplasm. We didn't find a role for host miRNAs in WMVB. Further analysis showed that the 3' end of the virus subgenomic RNA was protected and accumulated over time suggesting that the degradation is XRN1-mediated. We also found that sub genomic flavivirus RNA accumulation inactivated XRN1 in mosquito cells in the absence of Wolbachia and led to enhancement of RNA degradation in its presence. Depletion of XRN1 decreased WMVB which was associated with a significant increase in DENV RNA. We also observed that WMVB is influenced by virus MOI and rate of virus replication. A comparatively elevated blocking was observed for slowly replicating DENV, compared to WNV. Similar results were obtained while analysing different DENV serotypes. FAU - Thomas, Saijo AU - Thomas S AUID- ORCID: 0000-0002-3730-3588 AD - Institute of Vector-Borne Disease (IVBD), Monash University, Clayton, VIC, AUSTRALIA. FAU - Verma, Jiyoti AU - Verma J AD - Infection and Immunity Program, Biomedicine Discovery Institute and the Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC, AUSTRALIA. FAU - Woolfit, Megan AU - Woolfit M AD - Institute of Vector-Borne Disease (IVBD), Monash University, Clayton, VIC, AUSTRALIA. FAU - O'Neill, Scott L AU - O'Neill SL AD - Institute of Vector-Borne Disease (IVBD), Monash University, Clayton, VIC, AUSTRALIA. LA - eng GR - WT_/Wellcome Trust/United Kingdom PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20180301 PL - United States TA - PLoS Pathog JT - PLoS pathogens JID - 101238921 RN - 0 (MicroRNAs) RN - 0 (Microtubule-Associated Proteins) RN - 0 (RNA, Viral) RN - EC 3.1.- (Exoribonucleases) RN - EC 3.1.13.1 (XRN1 protein, human) SB - IM MH - Aedes/*immunology/metabolism/microbiology/virology MH - Animals MH - Dengue/immunology/*prevention & control/virology MH - Dengue Virus/physiology MH - Exoribonucleases/genetics/*metabolism MH - Humans MH - Insect Vectors/immunology/microbiology/virology MH - MicroRNAs MH - Microtubule-Associated Proteins/genetics/*metabolism MH - RNA, Viral/genetics/*metabolism MH - Symbiosis MH - *Virus Replication MH - West Nile Fever/immunology/*prevention & control/virology MH - West Nile virus/physiology MH - Wolbachia/*physiology PMC - PMC5833283 COIS- The authors have declared that no competing interests exist. EDAT- 2018/03/02 06:00 MHDA- 2018/06/27 06:00 PMCR- 2018/03/01 CRDT- 2018/03/02 06:00 PHST- 2018/01/11 00:00 [received] PHST- 2018/01/15 00:00 [accepted] PHST- 2018/03/02 06:00 [entrez] PHST- 2018/03/02 06:00 [pubmed] PHST- 2018/06/27 06:00 [medline] PHST- 2018/03/01 00:00 [pmc-release] AID - PPATHOGENS-D-18-00065 [pii] AID - 10.1371/journal.ppat.1006879 [doi] PST - epublish SO - PLoS Pathog. 2018 Mar 1;14(3):e1006879. doi: 10.1371/journal.ppat.1006879. eCollection 2018 Mar.